The skeleton is the second most frequent site of metastasis. However, only a restricted number of solid cancers, especially those of the breast and prostate, are responsible for the majority of the bone metastases. Metastatic bone disease is a major cause of morbidity, characterised by severe pain and high incidence of skeletal and haematopoietic complications (fractures, spinal cord compression and bone marrow aplasia) requiring hospitalisation. Despite the frequency of skeletal metastases, the molecular mechanisms for their propensity to colonise bone are poorly understood and treatment options are often unsatisfactory. TGF-b and the signalling pathway it controls appears to play major roles in the pathogenesis of many carcinomas, both in their early stages, when TGF-b acts to arrest growth of many cell types, and later in cancer progression when it contributes, paradoxically, to the phenotype of tumour invasiveness. Here we discuss some novel insights of the TGF-b superfamily-including BMPs and their antagonists-in the formation of bone metastasis. Increasing evidence suggests that the TGF-b superfamily is involved in bone homing, tumour dormancy, and development of micrometastases into overt bone metastases. The established role of TGF-b/BMPs and their antagonists in epithelial plasticity during embryonic development closely resembles neoplastic processes at the primary site as well as in (bone) metastasis. For instance, the tumour-stroma interactions occurring in the tissue of cancer origin, including epithelium-to-mesenchyme transition (EMT), bear similarities with the role of bone matrix-derived TGFb in skeletal metastasis formation.
Introduction
Transforming growth factor b (TGF-b) is a member of a large family of cytokines, which includes bone morphogenetic proteins (BMPs), Nodals, Activins and others, involved in the regulation of embryonic development and tissue homeostasis [1] . TGF-b family members, including their binding proteins and antagonists, are secreted by various cell types and regulate a vast array of cellular processes including cell proliferation, morphogenesis, migration, extracellular matrix production, angiogenesis, immune suppression, cytokine secretion and apoptosis [1] [2] [3] [4] . Bone morphogenetic proteins (BMPs), as the name already indicates, were first identified by their ability to induce ectopic chondro-osteogenesis in vivo [5, 6] . They play a crucial role in skeletal and joint morphogenesis, bone remodelling, and fracture repair by inducing proliferation, lineage determination, differentiation, and apoptosis in chondrocyte and osteoblast precursors [6, 7] . Subsequently, they were shown to act as multifunctional regulators of embryonic patterning and organogenesis, tissue remodelling, and repair [8, 9] . A crucial regulatory mechanism is the modulation of BMP signaling by a class of secreted molecules, BMP antagonists, functioning through direct association with BMPs, thereby sequestering BMPs in the extracellular space and preventing binding to cell surface receptors. Secreted cystein-knot-containing BMP antagonists have been divided in three subfamilies: the differential screening-selected gene aberrant in neuroblastoma (DAN), the twisted gastrulation, and the chordin/ noggin [10] . Antagonism of BMP activity by noggin and chordin is critical for embryonic chondro-osteogenesis and joint formation [11, 12] . The TGF-b and BMP pathways are modulated by many other signaling cascades and the TGF-b response is determined by the integration of the signals that a given cell receives [1] [2] [3] [4] .
TGF-b is a potent anti-proliferative factor in epithelial and haematopoietic cells. Moreover, it can act as an inducer of apoptosis in some cells. Several gene responses have been implicated in the apoptotic effects of TGF-b, some of which are mediated via Smad transcription factors [1] .
TGF-b/BMPs and their antagonists are important regulators of epithelial plasticity during embryonal morphogenesis, growth and tissue homeostasis.
Epithelial cells are polarised, express keratin filaments and membrane-associated specialised junctions such as desmosomes and adherens junctions. However, they can lose these epithelial features and acquire mesenchymal characteristics including flattened phenotype and expression of vimentin filaments [13, 14] . This process, named Epithelial-to-Mesenchymal Transition (EMT) [15] , leads to the acquisition of an invasive phenotype by epithelial cells that enables their migration into a new microenvironment and, eventually, their differentiation into distinct cell types. It is a highly conserved and fundamental process that governs morphogenesis during critical phases of embryonic development in multi-cellular organisms [14] . Examples of EMT during embryonic development include gastrulation (transition of epiblast to mesoderm) and the migration and delamination of neuroepithelial cells from the neural plate yielding bone muscle and the peripheral nervous system [16] .
Following EMT the cells may revert to an epithelial phenotype, which is induced by an opposite process, Mesenchymal-to-Epithelial Transition (MET) [17] .
While TGF-b is a potent inducer of EMT, another member of the TGF-b superfamily, the 35-kDa homodimeric protein Bone Morphogenetic Protein-7 (BMP7), has been shown to induce MET (and/or inhibit EMT) in nontransformed cells. For instance, during kidney development, BMP7 is essential for the condensation and epithelialisation of the metanephric mesenchyme in the kidney, forming the tubular epithelium [18, 19] . BMP7 appears to be involved in the preservation of the epithelial phenotype [20] , causes a decrease in epithelial cell apoptosis, and repression of inflammation.
EMT and MET are both non cell-autonomous processes, but typically require an external cue to be initiated. External signals or ''inducers'' are extra-cellular matrix components, and soluble factors that-besides members of the TGF-b superfamily [1, 21] -include Fibroblast Growth Factor (FGF) family [22] , Epidermal Growth Factor (EGF) [23] , Scattering Factor/Hepatocyte Growth Factor (SF/ HGF), Insulin-like Growth Factor-II (IGF-II) and proteins of the Wnt and Hedgehog [24] families [2, [25] [26] [27] [28] .
Parallelisms between embryonic development and carcinogenesis
During early carcinogenesis, the acquisition of local invasiveness includes major morphological phenotypic changes of cancer cells within the primary tumour. In order to acquire motility and invasiveness, carcinoma cells must shed many of their epithelial phenotypes/characteristics, detach from epithelial sheets, and undergo EMT. An EMT can also be observed at the edges of carcinomas that are invading adjacent tissues. This pathological process is strikingly similar to the EMTs occurring during early embryogenesis and wound healing. EMT involves a shedding by epithelial cells of their characteristic morphology and gene expression pattern and the assumption of a shape and transcriptional program characteristic of mesenchymal, migratory cells [2, 4, 16] .
The cellular changes associated with EMT encompass the loss of cytokeratin, E-cadherin expression and cell polarity. EMT also coincides with the acquisition of motility, invasiveness, vimentin, altered adhesion receptor expression and proteinase secretion. Tumours are, therefore, often viewed as corrupt forms of normal developmental processes and EMT is considered the most common fatal consequence in tumourigenesis [29] . It has also become increasingly clear that the changes in the tumour-surrounding stroma, for instance loss of TGF-b responsiveness in tumour-associated fibroblasts, is critical for the EMT induction and the acquisition of an invasive metastatic phenotype [30] . Furthermore, oncogenic EMTs are programmed by transcription factors that also orchestrate key steps of embryogenesis [4, 16] . Examples of this include snail, slug and twist transcription factors-potent E-cadherin suppressors-that were initially described in Drosophila. Similar to embryonic EMT, members of TGFb superfamily (TGF-bs, BMPs and their antagonists) are critical regulators of oncogenic EMT (and MET). Figures 1 and 2 depict an example of the effect of TGF-b in the acquisition of an invasive phenotype in normal human breast epithelium, premalignant and malignant breast cancer of the MCF10 series [31] . Clearly, TGF-b strongly stimulates the acquisition of an invasive phenotype in premalignant ras transformed breast epithelium and in breast carcinomas, while no EMT is observed in normal epithelium. Furthermore, TGF-b inhibited the proliferation of MCF10A1(normal breast epithelium) while the growth inhibitory and apoptotic effect were less/absent at later stages during tumour progression effect (results not shown). In addition, we found that challenging osteotropic cancers (human breast and prostate cancer cells) with TGFb strongly induced proteinase expression and expression of pro-angiogenic factors (Fig. 3) .
Our data are in line with the notion that TGF-b, due to its anti-proliferative and apoptotic functions, acts as a tumour suppressor at early stages during carcinogenesis. During tumour progression, cancer cells tend to lose the tumour-suppressive responses to TGF-b. Occasionally, malignant neoplastic cells acquire somatic mutations in components of the TGF-b-Smad signal transduction pathway (Smads and TGF-b receptors) in order to evade the TGF-b anti-proliferative function. In many other tumours, the TGF-b signal transduction pathway is not affected but cells become specifically resistant to the antiproliferative response to TGF-b. In those tumours, TGF-b can become an oncogenic factor, inducing proliferation, angiogenesis, invasion and metastasis [1, 4, 16] . In addition, TGF-b induces a blockade on the immune cellular proliferation and differentiation with a particular effect on T cells. Thus, in those tumours that are resistant to the TGF-b anti-proliferative response, TGF-b facilitates tumour progression by blocking the antitumoural immune response. Usually, tumours where TGF-b acts as an oncogenic factor express high levels of TGF-b, in many instances owing to the fact that TGF-b is able to induce its own expression generating a malignant autocrine loop [1, 16] .
The power of TGF-b to affect tumour development both positively and negatively has also been shown dramatically by experiments using a transgenic mouse model of skin carcinogenesis. In this model, squamous cell carcinoma development was favoured by the expression of a ras oncogene under control of a transcriptional Fig. 1 promoter that ensured its expression in keratinocytes of the skin. When a transgene favouring TGF-b in the skin was also installed in the germ line of these cancer-prone mice, the absolute number of skin tumours that formed was decreased, ostensibly because of the anti-proliferative effects of TGF-b [16] . However, those few tumours that did arise showed the phenotype of aggressive spindle-cell carcinomas (formed from cells that have undergone an EMT) rather than the more benign squamous cell carcinomas that are usually seen in such transgenic, tumourprone mice. Consequently, once transformed epithelial cells have developed a resistance to TGF-b's cytostatic effects (e.g. through inactivation of the pRb pathway) this factor can collaborate with oncogenes residing in the carcinoma cells to trigger an EMT and attendant highgrade malignancy [16] .
Bone metastasis; a continuing story of epithelial plasticity?
Whatever the mechanisms are that determine the arrest of cancer cells at a specific target tissue, these must survive and eventually proliferate in order to progress to a clinically manifest metastasis. The ''seed and soil'' hypothesis, first advanced by Paget in 1889, postulates that the microenvironment specific for a target tissue provides a fertile ground (''the soil''), which is permissive for the survival and growth requirements of the metastatic cancer cells (the ''seed'') [32] . Since then relevant experimental evidence in experimental models of bone metastasis has supported this view [33] [34] [35] .
Bone metastases are common in cancer, especially breast and prostate carcinoma and cause considerable morbidity [36] [37] [38] [39] [40] [41] . Evidence from clinical and experimental studies supports the concept that the rate of bone remodelling is directly related to the occurrence and progression of bone metastases [35, [42] [43] [44] .
The skeleton is a highly dynamic tissue that is continuously renewed through the process of bone remodelling. This occurs at multiple sites in the skeleton by temporary structures called 'basic multicellular units' (BMU) [45, 46] . The number and the activity of these BMUs determine the rate of bone turnover [47] . During bone remodelling osteoblasts and osteoclasts, the cellular components of the BMU, secrete paracrine factors that induce chemotaxis and cell adhesion, support cell survival and growth, and stimulate angiogenesis [48, 49] .
Mineralised bone matrices store varieties of growth factors including IGFs, TGF-b, PDGFs and BMPs. Furthermore, there is experimental evidence showing that growth factors like TGF-b are released from the bone matrix by bone resorbing osteoclasts and stimulate the secretion of bone active cytokines like PTHrP, which not only enhance bone resorption, but also stimulate further tumour growth ('vicious cycle') [48] [49] [50] [51] [52] [53] [54] . Yin and coworkers demonstrated that introduction of a dominantnegative TGF-bRII in MDA-MB-231 cells resulted in fewer and smaller osteolytic lesions in experimental model of bone metastasis [51] . They hypothesized that TGF-b released from the bone matrix by osteoclasts, enhance the production of the bone resorption stimulating cytokine PTHrP in osteolytic breast cancer cells. These bone resorption stimulators, therefore, in turn enhanced the release of TGF-b (and other matrix-bound factors) through stimulated osteoclastic activity, leading to a vicious cycle of bone metastasis [51, 52] .
It appears, therefore, that local concentrations of TGF-b may exists in close proximity to bone surfaces that are actively remodelling. Smad2 and 3 are phosphorylated by TGF-bRI (ALK5) and Smad1, 5 and 8 by BMPRI. They are commonly referred to as receptor phosphorylated Smads (R-Smads). Smad4, also called co-Smad, is a partner of the R-Smads and it is not phosphorylated by the TGF-b and BMP receptors. Moreover, two Smad proteins serve as inhibitors of the TGF-b and BMP signal, Smad6 and 7. They are not phosphorylated by the receptors and act as decoys interfering with Smad-receptor or Smad-Smad interaction as well as facilitating the proteasome-mediated degradation of the TGF-b receptors [1] . In experimental models of bone metastases with human breast and prostate cancer, the phosphorylated Smad2 transcription factor (indicative of active TGF-b signalling), was observed in bone metastatic cancer cells close to bone surfaces or at leading edges adjacent to bone marrow (Fig. 4) . Smad4 knockdown strongly inhibited TGF-b-induced EMT in mammary gland epithelial cells [55] . Furthermore, we and others showed that knockdown of Smad4 in MDA-MB-231 breast cancer cells strongly inhibited the frequency of bone metastasis and significantly increased metastasis-free survival [55, 56] . Figure 5 depicts an example of the growth inhibitory effects Smad4 knockdown in MDA-MB-231 [57] . We hypothesize that the activation process of micrometastases in bone marrow may bear similarities to EMT that occurs at the primary site in various epithelial cancers and during ontogeny (Fig. 6) . While TGF-b is a potent inducer of EMT and critically important in bone metastasis, another member of the TGF-b superfamily, the 35-kDa homodimeric protein BMP7, has been shown to induce MET (and/or inhibit EMT) in non-transformed cells by counteracting TGF-b signalling via Smad transcription factors.
We tested the hypothesis that BMP7 antagonises Smadmediated pro-tumour effects of TGF-b, thus inhibiting local cancer progression and the formation of bone metastases in vivo. Our data show that systemic BMP7 treatment significantly inhibited bone metastasis by human breast and prostate cancer cell lines in vivo [42, 43] . In line with these observations, functional studies with human MDA-MB-231 breast cancer cells that stably overexpress BMP7 revealed strong inhibition of bone metastasis in vivo. Moreover, tumourigenicity and invasive behavior is associated with diminished BMP7 expression in clinical prostate cancer specimens and in human cancer cell lines with different tumourigenic potential [42, 43] .
BMP7 counteracted TGF-b-induced nuclear translocation activation of activated Smad 3, 4 complexes and induced a dose-dependent expression of E-cadherin that led to an overall increase in E-cadherin/vimentin ratio as an established indicator of less-malignant and more epithelial phenotype. We, therefore, present evidence for cross talk between BMP7 and TGF-b signalling in the regulation of EMT in breast and prostate cancer. Our clinical findings suggest that decreased BMP7 expression is implicated in human breast and prostate cancer progression and we postulate a role for BMP7 in controlling epithelial [42, 43] homeostasis of the breast and prostate gland. In line with these clinical findings experimental treatment of bone metastases from human breast and prostate cancer in vivo position BMP7 as a good candidate for the treatment of skeletal metastasis from breast and prostate cancer. Considering the importance of TGF-b superfamily in bone metastasis [51] , our findings suggest that the efficacy of BMP7 in the experimental treatment of bone metastases is interfering with recapitulation of such cell plasticity of bone marrow micrometastatic cancer cells, particularly the acquisition of an invasive phenotype by (TGF-b driven?) EMT (Fig. 6) . Clinical studies also seem to underline the cellular plasticity of prostate cancer during dissemination and bone metastasis [58] [59] [60] . The transition from a welldifferentiated epithelial phenotype to an invasive mesenchymal phenotype may, of course, involve molecular mechanisms other than those described here. Other studies have provided evidence that motility and invasiveness can be enhanced without inducing a complete conversion of cellular identity [60] . After migrating to new organ or tissue territories, metastatic cancer cells can regain epithelial morphology by MET and re-establish E-cadherin expression and epithelial junctions [16, [58] [59] [60] . For instance, the observed reversion to an epithelial morphology in prostate cancer seems possible even at bone metastatic sites and is in full agreement with our in vitro and in vivo data [42, 43] .
Although little is known regarding the impact of bone (marrow) stromal cells in cancer bone metastasis, it can be argued that the production and release of specific growth factors, colony stimulating factors and cytokines like Wnts, that are critically important for the maintenance of the haematopoietic stem cells niche (and that regulate haematopoiesis), may also be essential for colonisation, survival and growth of cancer cells. Interestingly, TGF-b/BMPs and other pathways like wingless/Wnt, Notch, Hedgehog, appear not only to be involved in bone development/homeostasis and haematopoiesis but also in prostate cancer initiation and progression.
Moreover, the clinical manifestation of bone metastases, either osteolytic or osteoblastic or mixed phenotypes, appears also to be dependent on BMPs and Wnt proteins as osteoinductive molecules. Their activity is modulated by antagonists such as noggin and dickkopf-1. Recently, Schwaninger and co-workers demonstrated that forced noggin expression in an osteoinductive prostate cancer cell line abolished the osteoblast response induced in vivo [12] . Lack of noggin (and possibly dickkopf-1) expression by cancer cells may be a relevant mechanism contributing to the osteoblast response in bone metastases. Concomitant lack of osteolytic cytokines may be permissive of this effect.
Cancer stem cells and the bone metastatic process
It is becoming increasingly clear that tumour cell populations arising in breast and prostate are organised much like normal tissues, in which self-renewing stem cell populations are responsible for spawning the bulk of the cells [16] . In certain well-studied breast carcinomas, the bulk populations ([ [95%) of tumour cells behave much like the ''transit-amplifying'' cells found in a normal tissue. While the ''cancer stem cells'' are tumourigenic, in that they can seed a new tumour mass when implanted into the host, the non-stem cells (i.e., the transit-amplifying cells) in the tumour mass are unable to do so, because they are endowed with only a limited replicative potential [16] . Strikingly, TGF-b and BMPs play crucial roles during embryonic development and affect stem cell renewal and induction of differentiation into specialized-epithelial structures. These observations may have important implications for the process of metastasis. If the non-stem cells in a primary tumour mass are truly non-tumourigenic, then these cells may well succeed in leaving the primary tumour and lodging in distant sites, but they will be unable to colonise these sites because of their limited proliferative potential [16] . Accordingly, the ability to create macroscopic metastases may be limited to the relatively small number of tumour stem cells that escape from the primary tumour. These metastasis-initiating cells (MICs) may possess the ability to replicate to an unlimited extent and are therefore ideally suited to found new metastatic colonies that eventually expand to a life-threatening size. These dynamics may well contribute to metastatic inefficiency-the failure of the vast majority of disseminated cancer cells to colonise the tissue sites in which they have landed [16, 35, 42, 43, 61] . Moreover, these processes may well explain the heterogeneity in prognosis that is observed in patients without evidence of bone involvement at time of diagnosis or directly after removal or treatment of the primary tumour (minimal residual disease).
In many breast and prostate cancer patients, micrometastatic deposits may already exist in bone marrow after removal of the primary tumour that cannot be identified at the time of diagnosis (minimal residual disease). Whole body bioluminescent reporter imaging of luciferaseexpressing human breast and prostate cancer cells revealed that growth of micro-metastatic deposits in bone marrow are significantly inhibited by systemic administration of BMP7 [42, 43] . Interestingly, recent data suggest that BMPs can inhibit the tumourigenic potential of human brain-tumour initiating cells, mediated via a significant reduction in the stem-like, tumour initiating precursors [62] . Accumulating evidence suggests that cancer stem cells with tumour-initiating potential exist in human breast [63, 64] and prostate cancer [65] [66] [67] . Although speculative at present, the observed effects of TGF-b family members described above may be mediated, at least in part, by osteotropic cancer cells with tumour-initiating (and metastastic) potential. Further research is certainly warranted to address these important issues in bone metastasis formation and may, eventually, lead to better prediction which MRD patients are at risk of developing skeletal metastasis. Furthermore, identification and characterisation of metastasis-initiating cells may provide new strategies for the treatment of patients with (yet) uncurable metastatic bone disease.
